Category: BÜHLMANN Quantum Blue® fCAL Citations

US: BÜHLMANN Quantum Blue® fCAL is for Research Use Only. Not for use in diagnostic procedures in the US.
Canada: Quantum Blue® fCAL: Health Canada Licence: 83477 Quantum Blue® fCAL extended: Health Canada Licence: 100161
The citation list should be used for information only.

Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease

Quantum Blue® fCAL Citation: Ferreiro-Iglesias, R., Barreiro-de Acosta, M., Lorenzo-Gonzalez, A. & Dominguez-Muñoz, J. E. Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients Under Maintenance With Anti-TNF Therapy: A Prospective Longitudinal Cohort Study. J. Clin. Gastroenterol. (2016) PMID: remission, whereas concentrations >300 μg/g allow predicting relapse with a high probability at any
Continue Reading

Correlation of Rapid Point-of-Care vs Send-Out Fecal Calprotectin Monitoring in Pediatric Inflammatory Bowel Disease

BÜHLMANN Quantum Blue® fCAL extended Citation: Rodriguez, A. et al.  Correlation of rapid point-of-care vs send-out fecal calprotectin monitoring in pediatric inflammatory bowel disease. World J Gastrointest Pharmacol Ther 8(2):127-130. Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.127. Highlight from this Publication “In summary, we present the first correlation study of rapid POC calprotectin testing in a pediatric IBD
Continue Reading

The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease

BÜHLMANN Quantum Blue® fCAL Citation: Abej, E. et al. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory BowelDisease Can J Gastroenterol Hepatol. 2016;2016:2483261. Epub 2016 Sep 28.DOI:10.1155/2016/2483261.  PMID: 27774443.  This Canadian study represents how FCAL testing is utilized in the field for monitoring disease activity in IBD.  The reference for the cut-off
Continue Reading

FOCUS: Future of Fecal Calprotectin Utility Study in Inflammatory Bowel Disease

BÜHLMANN Quantum Blue® fCAL Citation: Rosenfeld G, Greenup A-J, Round A, et al. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World Journal of Gastroenterology. 2016;22(36):8211-8218. doi:10.3748/wjg.v22.i36.8211. PMID:27688663. Highlight from this Publication "The FC test effected a change in management 51.3% of the time and receipt of the result was associated with a reduction
Continue Reading

Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.

Quantum Blue® fCAL Citation: Ferreiro-Iglesias, R. Barreiro-de Acosta M, Otero Santiago M, Lorenzo Gonzalez A, Alonso de la Peña C, Benitez Estevez AJ, Dominguez-Muñoz JE., Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy. J Clin Gastroenterol. 2016 Feb;50(2):147-51. doi: 10.1097/MCG.0000000000000312. Highlight from this Publication “We found FC to
Continue Reading

Comparison of the Liaison® Calprotectin Kit with a Well-Established Point of Care Test (Quantum Blue — Bühlmann-Alere®) in Terms of Analytical Performances and Ability to Detect Relapses Amongst a Crohn Population in Follow-up

Quantum Blue®  fCAL Citation: Delefortrie, Q. Schatt P, Grimmelprez A, Gohy P, Deltour D, Collard G, Vankerkhoven P. Comparison of the Liaison® Calprotectin kit with a well-established point of care test (Quantum Blue — Bühlmann-Alere®) in terms of analytical performances and ability to detect relapses amongst a Crohn population in follow-up, Clinical Biochemistry. 2016 Feb;49(3):268-73. doi: 10.1016/j.clinbiochem.2015.10.010
Continue Reading

Rapid Fecal Calprotectin Level Assessment and the SIBDQ Score Can Accurately Detect Active Mucosal Inflammation in IBD Patients in Clinical Remission: a Prospective Study,

Quantum Blue® fCAL Citation: Voiosu T Benguş A, Dinu R, Voiosu AM, Bălănescu P, Băicuş C, Diculescu M, Voiosu R, Mateescu B.  Rapid Fecal Calprotectin Level Assessment and the SIBDQ Score Can Accurately Detect Active Mucosal Inflammation in IBD Patients in Clinical Remission: a Prospective Study, J Gastrointestin Liver Dis.  2014 Sep;23(3):273-8. doi: 10.15403/jgld.2014.1121.233.thv. Highlight from
Continue Reading

Comparison of Two Immunoassays for Measurement of Faecal Calprotectin in Detection of Inflammatory Bowel Disease: (Pre)-analytical and Diagnostic Performance Characteristics

Quantum Blue®  fCAL Citation Oyaert, M, Trouvé C, Baert F, De Smet D, Langlois M, Vanpoucke H.  Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics. Clin Chem Lab Med. 2014 Mar;52(3):391-7. doi: 10.1515/cclm-2013-0699. Highlight from this Publication “The Thermo Fisher device is not reliable for
Continue Reading

Comparative Study of the Quantum Blue Rapid Test and an Established ELISA Method

Quantum Blue®  fCAL Citation Coorevits, L, Baert F , Vanpoucke H.  Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method, Clinical chemistry and laboratory medicine: CCLM / FESCC. . 2013 Apr; 51(4):825-31. DOI:10.1515/cclm-2012-0386. “…we may conclude that the POCT can serve as reliable alternative to the time consuming ELISA…” Highlight from
Continue Reading

A New Rapid Test for Fecal Calprotectin Predicts Endoscopic Remission and Postoperative Recurrence in Crohn’s Disease.

Quantum Blue®  fCAL Citation Lobatón, T, , López-García A, Rodríguez-Moranta F, Ruiz A, Rodríguez L, Guardiola J. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's & colitis. J Crohns Colitis. 2013 Dec; 7(12):e641-51. doi: 10.1016/j.crohns.2013.05.005. Highlight from this Publication “FC determined by rapid quantitative test
Continue Reading